Huang Ching-Ya, Wu Shao-Chun, Yen Yuan-Hao, Yang Johnson Chia-Shen, Hsu Shiun-Yuan, Hsieh Ching-Hua
Department of Plastic Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.
Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.
Diagnostics (Basel). 2024 Sep 18;14(18):2065. doi: 10.3390/diagnostics14182065.
Early identification of high-risk traumatic brain injury (TBI) patients is crucial for optimizing treatment strategies and improving outcomes. The C-reactive protein-to-lymphocyte ratio (CLR) reflects systemic immunology and inflammation function and serves as a new biomarker for patient stratification. This study aimed to assess the predictive value of the CLR for mortality in patients with isolated moderate to severe TBI. A retrospective analysis of trauma registry data from 2009 to 2022 was conducted, including 1641 adult patients with isolated moderate to severe TBI. Patient demographics, the CLR, injury characteristics, and outcomes were compared between deceased and surviving patients. Univariate and multivariate analyses were performed to identify mortality risk factors. The optimal CLR cut-off value for predicting mortality was determined using receiver operating characteristic (ROC) curve analysis. The CLR was significantly higher in deceased patients compared to survivors (60.1 vs. 33.9, < 0.001). The optimal CLR cut-off value for predicting mortality was 54.5, with a sensitivity of 0.328 and a specificity of 0.812. The area under the ROC curve was 0.566, indicating poor discriminative ability. In the multivariate analysis, the CLR was not a significant independent predictor of mortality (OR 1.03, = 0.051). After propensity score matching to attenuate the difference in baseline characteristics, including sex, age, comorbidities, conscious level, and injury severity, the high-CLR group (CLR ≥ 54.5) did not have significantly higher mortality compared to the low-CLR group (CLR < 54.5). While the CLR was associated with mortality in TBI patients, it demonstrated poor discriminative ability as a standalone predictor. The association between a high CLR and worse outcomes may be primarily due to other baseline patient and injury characteristics, rather than the CLR itself.
早期识别高危创伤性脑损伤(TBI)患者对于优化治疗策略和改善预后至关重要。C反应蛋白与淋巴细胞比值(CLR)反映全身免疫和炎症功能,是用于患者分层的一种新生物标志物。本研究旨在评估CLR对孤立性中度至重度TBI患者死亡率的预测价值。对2009年至2022年创伤登记数据进行回顾性分析,纳入1641例孤立性中度至重度TBI成年患者。比较死亡患者和存活患者的人口统计学特征、CLR、损伤特征及预后。进行单因素和多因素分析以确定死亡危险因素。采用受试者工作特征(ROC)曲线分析确定预测死亡率的最佳CLR临界值。与存活患者相比,死亡患者的CLR显著更高(60.1对33.9,<0.001)。预测死亡率的最佳CLR临界值为54.5,敏感性为0.328,特异性为0.812。ROC曲线下面积为0.566,表明判别能力较差。在多因素分析中,CLR不是死亡率的显著独立预测因素(OR 1.03,=0.051)。在进行倾向评分匹配以减弱包括性别、年龄、合并症、意识水平和损伤严重程度等基线特征的差异后,高CLR组(CLR≥54.5)与低CLR组(CLR<54.5)相比,死亡率并无显著更高。虽然CLR与TBI患者的死亡率相关,但作为单一预测指标,其判别能力较差。高CLR与更差预后之间的关联可能主要归因于患者和损伤的其他基线特征,而非CLR本身。